Price
No data yet.
Social Signal Score
Revenue
$0.00-100.00%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Stephen Anthony Stamp
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 11
- Beta
- 1.24
- Country
- GB
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- -10.54
Financials
Revenue
$0.00-100.0%Net Income
$-2.56MEBITDA
$-4.68MFree Cash Flow
$-2.33MEPS (diluted)
$-50.00Shares Outstanding (diluted)
90.3K+1128987.5%Operating Expenses
$4.74MCash & Debt
$8.52MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-6.24M | $-400.00 |
| 2024 | $0.00 | $-5.73M | $-3705.65 |
| 2023 | $381.0K | $-7.08M | $-69640.00 |
| 2022 | $699.0K | $-7.66M | $-4770680.00 |
| 2021 | $578.0K | $-5.46M | $-4661590.00 |
| 2020 | $343.0K | $-22.19M | $-33209775.00 |
| 2019 | $674.0K | $-10.09M | $-35095575.00 |
| 2018 | $1.94M | $-10.37M | $-292803790.00 |
| 2017 | $989.0K | $-11.71M | $-397196150.00 |
| 2016 | $1.32M | $-6.16M | $-740868715.00 |
| 2015 | $1.38M | $-10.10M | $-536944425.00 |
| 2014 | $157.0K | $-8.82M | $-1577747295.00 |
| 2013 | $147.0K | $-4.08M | $-229264380.00 |
| 2012 | $0.00 | $-3.99M | $-216922555.00 |
Valuation
BDRXhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
100Social Signal Score
Mentions (1)
- Newsglobenewswire.com·5h ago·Neutral
…Biodexa announces major milestone for its Serenta registrational Phase 3 trial in FAP 87 subjects, over 50% of target, recruited Biodexa Pharmaceuticals PLC (Nasdaq: BDRX) (“Biodexa” or “the Company”), a clinical stage biopharmaceutical company developing innovative products focused on the treatment or prevention of gastrointestinal cancers is pleased to announce that it has exceeded the half-way point in the recruitment of subjects in its registrational Phase 3 trial of eRapa in Familial Adenom…
View source ↗
Earnings
Fri, Sep 11(in 3 weeks)
Typical surprise -2.6% (median, so one quarter with a near-zero estimate can't distort it)
- Fri, Mar 27$-0.00 vs $-0.01beat
- Fri, Sep 12$-0.00 vs $-0.02beat
- Fri, Apr 11$-0.03 vs $-0.03miss
- Thu, Sep 26$-1.67 vs $-1.12miss
- Fri, Apr 19$-17.72 vs $-17.71miss
Estimates and results for BDRX via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by BDRX officers and directors.
No open-market trades in the recent filings. All 12 recent Form 4 entries were share awards, option exercises or tax withholding — pay, not decisions to buy or sell.
12 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.